CytomX Therapeutics, Inc.
CTMX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001501989
No open-market purchases or sales by CytomX Therapeutics, Inc. insiders were filed in the last 90 days; 178 institutions reported holding it in 13F filings for Q2 2026, worth $799.0M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding CytomX Therapeutics, Inc. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 114 | 110 | −4 |
| Shares | 54.0M | 54.5M | +560.9K (+1.0%) |
| Value | $274.8M | $236.5M | −$38.3M (−13.9%) |
New holders (21)
Institutions that held CytomX Therapeutics, Inc. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BVF Inc | 5,803,700 | $25.1M | 0.91% |
| Rubric Capital Management LP | 2,406,449 | $10.4M | 0.49% |
| Pictet Asset Management SA | 288,326 | $1.25M | 0.00% |
| Tang Capital Management LLC | 152,345 | $660.0K | 0.13% |
| Clearline Capital LP | 145,000 | $628.0K | 0.09% |
| Allspring Global Investments Holdings, LLC | 90,846 | $393.0K | 0.00% |
| Engineers Gate Manager LP | 68,953 | $299.0K | 0.01% |
| Virtu Financial LLC | 52,434 | $227.0K | 0.02% |
| Sender Co & Partners, Inc. | 40,720 | $176.0K | 0.11% |
| Citadel Advisors LLC | 38,070 | $165.0K | 0.00% |
| Quantbot Technologies LP | 25,154 | $108.0K | 0.01% |
| Alpine Global Management, LLC | 22,184 | $96.0K | 0.01% |
| Schonfeld Strategic Advisors LLC | 19,800 | $85.0K | 0.00% |
| Jane Street Group, LLC | 18,820 | $81.0K | 0.00% |
| Manteio Capital LLC | 15,067 | $65.0K | 0.08% |
| Clear Harbor Asset Management, LLC | 11,440 | $50.0K | 0.01% |
| Raymond James Financial Services Advisors, Inc. | 10,227 | $44.0K | 0.00% |
| XTX Topco Ltd | 10,165 | $44.0K | 0.02% |
| Group One Trading, L.P. | 1,511 | $7.00K | 0.00% |
| Aquatic Capital Management LLC | 600 | $3.00K | 0.01% |
| US Bancorp | 50 | $0 | 0.00% |
Sold out (25)
Institutions that held CytomX Therapeutics, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.